Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism

OBJECTIVE: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). We evaluated whether MPC inhibitors (MPCi) might correct impairments in branched chain amino acid (BCAA) catabolism, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Daniel, Eichler, Sophie J., Yiew, Nicole K.H., Colca, Jerry R., Cho, Kevin, Patti, Gary J., Shew, Trevor M., Lutkewitte, Andrew J., Mukherjee, Sandip, McCommis, Kyle S., Niemi, Natalie M., Finck, Brian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989691/
https://www.ncbi.nlm.nih.gov/pubmed/36801448
http://dx.doi.org/10.1016/j.molmet.2023.101694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989691/
https://www.ncbi.nlm.nih.gov/pubmed/36801448
http://dx.doi.org/10.1016/j.molmet.2023.101694

Ejemplares similares